On the evening of April 14, Weiming Pharmaceutical (002581) received a letter of concern from Shenzhen Stock Exchange, which involved matters related to the removal of the general manager of the company. According to the announcement of Weiming pharmaceutical, on April 12, the company announced the resignation of general manager Ding XueGuo. One day later, the board of directors of Weiming pharmaceutical deliberated and passed the motion on removing Ding XueGuo from the post of general manager of the company. However, during the deliberation of the above-mentioned motion, Yu Xiuyuan, director of Weiming pharmaceutical, voted against the motion on the ground that “it is understood that general manager Ding XueGuo has never resigned in any form”, which also made Weiming pharmaceutical fall into the suspicion of personnel change. In the letter of concern, the authenticity of Ding XueGuo’s resignation was questioned.
On April 12, Weiming pharmaceutical announced that the board of directors of the company had received a letter from the chairman of the company approving Ding XueGuo’s resignation as the general manager of the company. At this point, Ding XueGuo will no longer be the general manager of Xiamen Weiming biomedical Co., Ltd., a wholly-owned subsidiary of the company, and the chairman and manager of Tianjin Weiming biomedical Co., Ltd., a holding subsidiary of the company.
At that time, Weiming pharmaceutical said that as of the announcement date, Ding XueGuo did not hold shares in the company. From now on, according to Article 128 of the articles of association, the joint general managers shall perform their duties.
On April 13, Weiming pharmaceutical held the 17th meeting of the 4th board of directors, which deliberated and passed the proposal on removing the general manager of the company. From the voting situation, 9 of them were in favor and 1 was against. Specifically, Yu Xiuyuan, director of Weiming pharmaceutical, voted against the motion on the removal of the general manager of the company on the grounds that “it is understood that general manager Ding XueGuo has never resigned in any form, and the sudden removal of key senior executives will have a significant negative impact on the company.”.
In this regard, the Shenzhen Stock Exchange issued a letter of concern, asking Weiming pharmaceutical to explain the reasons for the removal of Ding XueGuo from the post of general manager in the case of Ding XueGuo’s resignation, the specific effective time of Ding XueGuo’s departure, to supplement Ding XueGuo’s written resignation report, and to ask the lawyer to express clear opinions on the time of departure; at the same time, Yu Xiuyuan was required to explain the above situation in detail And asked Weiming medicine to check whether the above situation is true.
Shenzhen Stock Exchange also asked unnamed independent directors to verify the reasons for the resignation of the general manager, and the independent directors of the company explained in detail the verification process and the basis for their opinions.
In view of the company’s related problems, a reporter from Beijing Business Daily called the office of the Board Secretary of Weiming medicine for an interview, but no one answered the phone.
On April 13, the board of directors of Weiming pharmaceutical also deliberated and passed the proposal on the transfer of the project of “recombinant human NGF eye drops” and the proposed establishment of a joint venture project company (hereinafter referred to as the proposal on the project of “recombinant human NGF eye drops”). The board of supervisors of Weiming medicine deliberated on the project proposal of “recombinant human NGF eye drops”, in which two supervisors voted against it, but the above proposal was not approved by the board of supervisors. Yu Xiuyuan, director of Weiming pharmaceutical, and Yan Xueming and Yu Wenjie, two supervisors, expressed their opposition to the proposal on the project of “recombinant human NGF eye drops” on the grounds that “it is more beneficial for the development of the project to set up a joint venture company directly by the R & D subject”.
Shenzhen stock exchange requires unnamed pharmaceutical to explain in detail the reasons for making the above project arrangement, whether it will have adverse effects on the normal progress of the project, and whether the amount involved in the above project cooperation plan meets the criteria of the general meeting of shareholders. In addition, the above motion has not been deliberated and passed by the board of supervisors, and the company needs to explain the validity of the motion.
Beijing Business News (reporter Liu Fengru)
[the above content is transferred from “Beijing Business Daily website”, which does not represent the view of this website. If you need to reprint it, please get permission from the website of Beijing business daily. If there is any infringement, please contact to delete it. 】